

RECEIVED JUL 0 8 2003 TC 1700

Attorney Docket No. 56822(47126)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

G. CEVC et al.

U.S.S.N.:

10/037,480

ART UNIT:

1723

FILED:

January 4, 2002

EXAMINER:

Unknown

FOR:

A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS

ADAPTABLE SEMI-PERMEABLE BARRIERS

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 2, 2003

y: Lleen (Y) Woodbury
Eileen M. Woodbury

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE)

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

U.S.S.N.: 10/037,480 Page 2 II. COPIES a. <u>X</u> Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed. Each of the patents, publications or other information listed b. ___ on the attached PTO-1449 was previously cited by or submitted to the USPTO in connection with U.S.S.N.: _____, to which the subject application claims the benefit of the earlier filing date. As such, a copy of each is not included herewith pursuant to 37 C.F.R. § 1.98(d). III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box) Except as may be indicated below in (b), all of the patents, a. X_ publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required). A concise explanation of the relevance of all patents, b. ___ publications or other information listed that is not in the English language is as follows: _ English translation for reference(s) _____. _ English abstract for reference(s) ___. _ English translation of search report/official communication. Copy of PCT/EPO Search Report. The following additional information is provided for the Examiner's consideration: Copy of EPO Search Report. Copy of PCT Search Report. Copy of Official Communication from the ____ Patent Office. English translation of search report/ official communication. Copy of ______

G. CEVC et al.

G. CEVC *et al*. U.S.S.N.: 10/037,480 Page 3

FEES

IV.	THIS IDS IS	BEING FILED UNDER 37 C.F.R. § 1.97(b)
	(check one b	oox)
	a	within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
	b	within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
	c. <u>X</u>	before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e)below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).
V.	THIS IDS IS (check one b	BEING FILED UNDER 37 C.F.R. § 1.97(c):
	(See 37 C.F.)	R. § 1.97(c) (1)) or before the mailing date of a Notice of order 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).
	a	No certification; therefore, a fee in the amount of \$240.00 is required by 37 C.F.R § 1.17(p).
	b	or See the certification below. No fee is required.

G. CEVC et al.

U.S.S.N.: 10/037,480

Page 4

VI. <u>CERTIFICATION UNDER 37 C.F.R. § 1.97(e)</u> (check <u>only</u> one box)

The unde	rsigned hereby certifies that
a. _.	each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpar foreign application not more than three months prior to the filing of this IDS; or
b	no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpar foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
с	Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpar foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpar foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
VII. <u>FE</u>	E PAYMENT (check one)
	Enclosed please find a check in the amount of \$240.00 for the above-indicated fee.
	Please charge Deposit Account No. 04-1105 in the amount of \$240.00 for the above-indicated fee.
	No fee is required

G. CEVC et al.

U.S.S.N.: 10/037,480

Page 5

If the Examiner has any questions concerning the IDS, he/she is requested to contact the undersigned. If it is determined that the IDS has been filed under the wrong rule, the PTO is requested to consider the IDS under the proper rule, with a petition if necessary, and charge the appropriate fee to

Deposit Account No. 04-1105.

Lisa Swiszcz Hazzard (Reg. 44,368)

Intellectual Property Practice Law Group EDWARDS & ANGELL, LLP

P.O. Box 9169

Boston, MA 02209

617-439-4444

Customer No.: 21874

BOS2_316220.1

OIPE CATO

SERIAL NO.: 10/037,480 DOCKET NO: FORM PTO-1449 56822 (47126) APPLICANT: G. CEVC et al. INFORMATION DISCLOSURE FILING DATE: GROUP NO. STATEMENT January 4, 2002 1723 UNITED STATES PATENT DOCUMENTS EXAM. DOCUMENT FILING DATE INITIALS NUMBER DATE NAME CLASS SUBCLASS | IF APPROPRIATE 09/04/90 Miller AA 4,954,345 AB 06/26/90 Mezei, et al. 4,937,078 AC 4,921,706 05/01/90 Roberts, et al. AD 4,911,928 03/27/90 Wallach 12/26/2000 G. CEVC ΑE 6,165,500 FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION DATE **CLASS SUBCLASS** YES/NO NUMBER COUNTRY PCT BA WO 98/17255 04/30/98 BB WO 98/30215 07/16/98 PCT BC WO 92/03122 03/05/92 PCT BD WO 00/24377 05/04/00 PCT BE WO 0 0/12060 03/09/00 PCT BFWO 98/33483 08/06/98 PCT BG WO 88/07362 10/06/88 **PCT** BH WO 00/38653 07/06/00 PCT PCT BI WO 98/06750 02/19/98 BJ WO 91/04013 04/04/91 **PCT** BK WO 92/05771 04/16/92 **PCT**

BOS2_316224.1

EXAMINER:

BL WO 93/19736

BM WO 93/19737

10/14/93

10/14/93

PCT

PCT

DATE:



TO STORY DOCKET NO: SERIAL NO.: 56822 (47126) 10/037,480 APPLICANT: G. CEVC et al. INFORMATION DISCLOSURE STATEMENT FILING DATE: GROUP NO. January 4, 2002 1723 UNITED STATES PATENT DOCUMENTS EXAM. **DOCUMENT** FILING DATE INITIALS NUMBER NAME CLASS SUBCLASS IF APPROPRIATE DATE FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION NUMBER DATE COUNTRY **CLASS SUBCLASS** YES/NO BN WO 90/09782 09/07/90 PCT во WO 87/01938 04/09/87 PCT BP 4,447,287 11/07/96 Germany BO 3,713,494 10/29/87 Germany BR 3,016,976 11/13/80 Germany BS 1,289,420 09/24/91 Canada BT 2,052,164 09/26/92 Canada BU 1,740,283 07/28/83 AU BV0,674,913 04.10.95 Europe BW 0,704,206 04/03/96 Europe BX 0,475,160 03/18/92 Europe BY 0,707,847 04/24/96 Europe BZ 0,475,160 03/18/92 Europe DA 0,280,492 08/31/88 Europe DB 0,102,324 03/07/84 Europe DC 11/24/86 0,224,837 Europe 02/25/87 DD 0,211,647 Europe DE 0,220,797 05/06/87 Europe EXAMINER: DATE:



FORM PTO-1449				DOCKET NO:		L NO.:		
				56822 (47126) 10/037,480		02 1		
Information disclosure				APPLICANT: G. CEVC et al.			(S. (S)	
STATEMENT				FILING DATE:	GROUP N	o. C		
				January 4, 2002	1723	1723		
UNIT				D STATES PATENT DOCU	JMENTS	ENTS		
EXAM.		DOCUMENT					FILING DATE	
INITIALS		NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIATE	
		T	FOI	REIGN PATENT DOCUME	NTS	<u> </u>	T	
		DOCUMENT			a		TRANSLATION	
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES/NO	
]			OTHER ROCHMENTS		<u></u>		
•	CA	G CEVC et al	Transfersome	OTHER DOCUMENTS	d delivery in	nnroves the re	gio-specificity and	
	CA	G. CEVC et al., Transfersomes-mediated transepidermal delivery improves the regio-specificity and biological actibity of corticosteroids in vivo, <i>Journal of Controlled Release</i> 45 (1997) 211-226.						
	СВ	B V.M. KNEP P et al. CONTROLLED DRUG RELEASE FROM A NOVEL LIPOSOMAL DELIVERY SYSTEM II. TRANSDERMAL DELIVERY CHARACTERISTICS", Journal of Controlled Release 12 (1990) March, No. 1, Amsterdam, NL, pp. 25-30. C C.E. Price, "A REVIEW OF THE F ACTORS INFLUENCING THE PENETRATION OF PESTICIDES THROUGH PLANT LEAVES" on I.C.I. Ltd., Plant Protection Division, Jealott's Hill Research Stat Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252.						
	CC							
	CD	CD K. Karzel and R. K. Liedtke, "MECHANISMEN TRANSKUTANER RESORPTION" on Grandlagen/Basics, pp. 1487-1491.						
	CE	E Micha el Mezei, "LIPOSOMES AS A SKIN DRUG DELIVERY SYSTEM" 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp. 345-358.						
	CF	Adrienn Gesztes and Michael Mezei, "TOPICAL ANESTHESIA OF THE SKIN BY LIPOSOME-ENCAPSULATED TETRACAINE" on Anesth Analg 1988; 67: pp. 1079-81.						
	CG	A. Helenius, et al, "SOLUBILIZATION OF MEMBRANES BY DETERGENTS", Biochimica et Biophysica Acta, 415 (1975) 29-79.						
	СН	Phillip G. Green, et al., "IN VITRO AND IN VIVO ENHANCEMENT OF SKIN PERMEATION WITH OLEIC AND LAURIC ACIDS" on International Journal of Pharmaceutics, 48 (1988), pp. 103-111.						
	CI	CI Guia M. Golden et al. "ROLE OF STRATUM CORNEUM LIPID FLUIDITY IN TRANSDERMAL DRUG FLUX" on Journal of Pharmaceutical Sciences Vol. 76, No. 1, January 1987, American Pharmaceutical Association, pp. 25-28.						
	CJ Bruce J. Aungst et al., "ENHANCEMENT OF NALOXONE PENETRATION THROUGH HUMAN SKIN IN VITRO USING FATTY ACIDS, FATTY ALCOHOLS, SURFACTANTS, SULFOXIDES AND AMIDES on International Journal of Pharmaceutics, 33 (1986) pp. 225-234.							
		on internationa	I Journal of F	marmaceutics, 33 (1980) j	p. 223-234	•		



FORM PTO-1449				DOCKET NO: SERIAL NO.: 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			RECEIVED TO
INFORMATION DISCLOSURE			0				
STATEMENT				FILING DATE: GROUP NO.			
				January 4, 2002	1723		
			UNITE	D STATES PATENT DO	CUMENTS		
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
•			FO	 REIGN PATENT DOCUM	IENTS	<u> </u>	
		DOCUMENT					TRANSLATION
<u></u>		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES/NO
•							
				OTHER DOCUMENTS	3		
		T					
	СК	EXCISED HUM	AN SKIN DU	CHARACTERIZATION OF RING LONTOPHORESIS merican Pharmaceutical	on Journal	of Pharmaceut	
		EXCISED HUM 76, No. 10, Oct E.C. Katoulis et MONITORING (AN SKIN DUI ober 1987, A t al., "EFFICA OF BLOOD G	RING LONTOPHORESIS'	on Journal Association ESS INSULI S AND FRE	of Pharmaceut , pp. 765-773. N DELIVERY SY E INSULIN LEV	ical Sciences Vol. STEM
	CL	EXCISED HUM 76, No. 10, Oct E.C. Katoulis et MONITORING (International Jo Ovals Siddiqui	AN SKIN DUI ober 1987, And tal., "EFFICA OF BLOOD Gournal of Arti et al., "NONP	RING LONTOPHORESIS merican Pharmaceutical ACY OF A NEW NEEDEL LUCOSE FLUCTUATION	on Journal Association ESS INSULI S AND FRE . 5, 1989, p RATION OF	of Pharmaceut, pp. 765-773. N DELIVERY SYE INSULIN LEV. p. 333-338. PEPTIDE AND I	STEM ELS" on PROTEIN DRUGS"
	CL	EXCISED HUM 76, No. 10, Oct E.C. Katoulis et MONITORING (International Jo Ovals Siddiqui on CRC Critical Cevc, G. et al., " resistance and	AN SKIN DUI ober 1987, A t al., "EFFICA OF BLOOD G ournal of Arti et al., "NONP I Reviews in T Ul traflexible transport the	RING LONTOPHORESIS merican Pharmaceutical ACY OF A NEW NEEDEL LUCOSE FLUCTUATION ficial Organs Vol. 12, Notate ARENTERAL ADMINIST	on Journal Association ESS INSULI S AND FRE 5, 1989, p RATION OF Systems, V , have an ex ulin across	of Pharmaceut, pp. 765-773. N DELIVERY SYE INSULIN LEVED. 333-338. PEPTIDE AND Folume 3, Issue tremely low por	STEM ELS" on PROTEIN DRUGS" 3, pp. 195-208. e penetration
	CL CM	EXCISED HUM 76, No. 10, Oct E.C. Katoulis et MONITORING (International Jo Ovals Siddiqui on CRC Critical Cevc, G. et al., " resistance and Biochimica et E Cevc, G. "Mater	AN SKIN DUI ober 1987, And all, "EFFICA OF BLOOD Gournal of Arti- et al., "NONP Reviews in Tull traflexible transport the Biophysica Actial Transport	RING LONTOPHORESIS' merican Pharmaceutical ACY OF A NEW NEEDEL LUCOSE FLUCTUATION (ficial Organs Vol. 12, Not ARENTERAL ADMINIST) Therapeutic Drug Carrier vesicles, Transfersomes erapeutic amounts of ins	on Journal Association ESS INSULI S AND FRE . 5, 1989, p RATION OF Systems, V , have an exulin across 998).	of Pharmaceut, pp. 765-773. N DELIVERY SYE INSULIN LEVED. 333-338. PEPTIDE AND Folume 3, Issuestremely low porthe intact mamin	STEM ELS" on PROTEIN DRUGS" 3, pp. 195-208. e penetration malian skin",
	CM CN	EXCISED HUM 76, No. 10, Oct E.C. Katoulis et MONITORING (International Jo Ovals Siddiqui on CRC Critical Cevc, G. et al., " resistance and Biochimica et E Cevc, G. "Mater Biological Physi Mayer, L.D. et a	AN SKIN DUI ober 1987, And all, "EFFICA OF BLOOD Gournal of Arti- et al., "NONP Reviews in Tull traflexible transport the Biophysica Activity and Transport ics, Vol. 1, pp. al., "Vesicles of	RING LONTOPHORESIS' merican Pharmaceutical ACY OF A NEW NEEDEL LUCOSE FLUCTUATION ficial Organs Vol. 12, Notate ARENTERAL ADMINISTIC Cherapeutic Drug Carrier vesicles, Transfersomes erapeutic amounts of instata. 1368 pp. 201-215 (1922) Across Permeability Batterican Pharmaceutical Pharmaceu	on Journal Association ESS INSULI S AND FRE . 5, 1989, p RATION OF Systems, V , have an exulin across 1998).	of Pharmaceut, pp. 765-773. N DELIVERY SYE INSULIN LEVED. 333-338. PEPTIDE AND Folume 3, Issuestremely low porthe intact maminants of Lipid Vesting Street, pp. 250-250. The intact maminants of Lipid Vesting Street, pp. 260-270.	ical Sciences Vol. STEM ELS" on PROTEIN DRUGS" 3, pp. 195-208. e penetration malian skin", sicles", Handbook of
	CM CN CO	EXCISED HUM 76, No. 10, Oct E.C. Katoulis et MONITORING (International Jo Ovals Siddiqui on CRC Critical Cevc, G. et al., " resistance and Biochimica et E Cevc, G. "Mater Biological Physi Mayer, L.D. et a Biochimica et E Patel, H.M. et a	AN SKIN DUI ober 1987, And all, "EFFICA OF BLOOD Gournal of Arti- et al., "NONP I Reviews in Tull traflexible transport the Biophysica Actial Transport ics, Vol. 1, pp. al., "Vesicles of Biophysica Action, "Vesicles of Biophysica Action," ORAL AD	RING LONTOPHORESIS' merican Pharmaceutical ACY OF A NEW NEEDEL LUCOSE FLUCTUATION ficial Organs Vol. 12, Not ARENTERAL ADMINISTIC Therapeutic Drug Carrier vesicles, Transfersomes trapeutic amounts of instata. 1368 pp. 201-215 (1922). Across Permeability Bato. 465-490 (1995).	on Journal Association Association ESS INSULI S AND FRE . 5, 1989, p RATION OF Systems, V , have an exulin across 1998). Triers by Meded by a rapid S6). ELIN BY ENCORAGE.	of Pharmaceut, pp. 765-773. N DELIVERY SYE INSULIN LEVED. 333-338. PEPTIDE AND Folume 3, Issuestremely low porthe intact mammans of Lipid Vester description produced and the contract of the intact mammans of Lipid Vester description produced and the contract of the contract of Lipid Vester description produced and Lipid Vester description produ	ical Sciences Vol. STEM ELS" on PROTEIN DRUGS" 3, pp. 195-208. e penetration malian skin", sicles", Handbook of
	CM CN CO CP	EXCISED HUM 76, No. 10, Oct E.C. Katoulis et MONITORING (International Jo Ovals Siddiqui on CRC Critical Cevc, G. et al., " resistance and Biochimica et E Cevc, G. "Mater Biological Physi Mayer, L.D. et a Biochimica et E Patel, H.M. et a LIPOSOMES", I Schreier, H. "Lip	AN SKIN DUI ober 1987, And an all, "EFFICA OF BLOOD Gournal of Arti- et al., "NONP I Reviews in Tournal of Arti- et al., "NONP I Reviews in Tournal of Arti- tics, and an all the Biophysica Acti- cial Transport ics, Vol. 1, pp. al., "Vesicles of Biophysica Action of Biophysica Actio	RING LONTOPHORESIS' merican Pharmaceutical ACY OF A NEW NEEDEL LUCOSE FLUCTUATION official Organs Vol. 12, Not ARENTERAL ADMINISTIC Therapeutic Drug Carried vesicles, Transfersomes erapeutic amounts of instata. 1368 pp. 201-215 (1922). Across Permeability Battle, 465-490 (1995). Of variables sizes producta, 858 pp. 161-165 (1922). MINISTRATION OF INSU	on Journal Association Association ESS INSULI S AND FRE . 5, 1989, p RATION OF Systems, V , have an exulin across 1998). Triers by Meded by a rapid S6). LIN BY ENC 1976).	of Pharmaceut, pp. 765-773. N DELIVERY SYE INSULIN LEVED. 333-338. PEPTIDE AND Folume 3, Issuestremely low porthe intact maminans of Lipid Vesta dextrusion process. CAPSULATION Vesta Production and process.	ical Sciences Vol. STEM ELS" on PROTEIN DRUGS" 3, pp. 195-208. e penetration malian skin", sicles", Handbook of cedure", VITHIN
	CM CN CO CP CQ CR	EXCISED HUM 76, No. 10, Oct E.C. Katoulis et MONITORING (International Jo Ovals Siddiqui on CRC Critical Cevc, G. et al., " resistance and Biochimica et E Cevc, G. "Mater Biological Physi Mayer, L.D. et a Biochimica et E Patel, H.M. et a LIPOSOMES", F Schreier, H. "Lip of Liposomes; II (1982).	AN SKIN DUI ober 1987, And all, "EFFICA OF BLOOD Gournal of Arti- et al., "NONP I Reviews in Tour Ul traflexible transport the Biophysica Actial Transport ics, Vol. 1, pp. al., "Vesicles of Biophysica Action, "Vesicles of Biophysica Action, "ORAL AD FEBS LETTER oos omes – A I. Destiny of I	RING LONTOPHORESIS' merican Pharmaceutical ACY OF A NEW NEEDEL LUCOSE FLUCTUATION official Organs Vol. 12, Not ARENTERAL ADMINISTIC Therapeutic Drug Carrier vesicles, Transfersomes erapeutic amounts of instata. 1368 pp. 201-215 (1922). Across Permeability Battle, 465-490 (1995). Of variables sizes producta, 858 pp. 161-165 (1922). MINISTRATION OF INSURS, 62(1):60-63 (Februar Novel Drug Carrier, I. Physical Across Productaria (1995).	on Journal Association Association ESS INSULI S AND FRE . 5, 1989, p RATION OF Systems, V , have an exulin across 1998). Triers by Med by a rapid S6). ILIN BY ENC 1976). Toppholipids therapy", Plant Service Serv	of Pharmaceut, pp. 765-773. N DELIVERY SYE INSULIN LEVED. 333-338. PEPTIDE AND Folume 3, Issuestremely low porthe intact maminants of Lipid Vesta dextrusion processors. CAPSULATION VERNELLE IN UNITY OF THE INTERIOR INTERIOR IN UNITY OF THE INTERIOR INTE	ical Sciences Vol. STEM ELS" on PROTEIN DRUGS" 3, pp. 195-208. e penetration malian skin", sicles", Handbook of cedure", VITHIN
	CL CM CN CO CP CQ CR	EXCISED HUM 76, No. 10, Oct E.C. Katoulis et MONITORING (International Jo Ovals Siddiqui on CRC Critical Cevc, G. et al., " resistance and Biochimica et E Cevc, G. "Mater Biological Physi Mayer, L.D. et a Biochimica et E Patel, H.M. et a LIPOSOMES", F Schreier, H. "Lip of Liposomes; II (1982). Beyer, C. et al., Lichtenberg, D.	AN SKIN DUI ober 1987, And a state of the st	RING LONTOPHORESIS' merican Pharmaceutical ACY OF A NEW NEEDEL LUCOSE FLUCTUATION official Organs Vol. 12, Not ARENTERAL ADMINISTIC Therapeutic Drug Carrier vesicles, Transfersomes erapeutic amounts of instata. 1368 pp. 201-215 (1922). Across Permeability Battle, 465-490 (1995). Of variables sizes producta, 858 pp. 161-165 (1922). MINISTRATION OF INSURS, 62(1):60-63 (Februar Novel Drug Carrier, I. Phiposomes in vivo; use in	on Journal Association Association ESS INSULI S AND FRE . 5, 1989, p RATION OF Systems, V , have an exulin across 1998). Triers by Med by a rapid S6). LIN BY ENCY 1976). LIN BY ENCY 1976). LIN BY ENCY 1976). LOSPHOLIPIDS B	of Pharmaceut, pp. 765-773. N DELIVERY SYE INSULIN LEVED. 333-338. PEPTIDE AND Folume 3, Issuestremely low porthe intact mammals of Lipid Vester and Capsulation process. Production and Capsulation and Ca	STEM ELS" on PROTEIN DRUGS" 3, pp. 195-208. e penetration malian skin", sicles", Handbook of cedure", VITHIN d Characterization erer Zeit, No. 4

/	OIPE	
(.	JUL 0 7 2803 2)	
13	MADEN	

Te marget	/						D	
FORM PT	0-14	49		DOCKET NO: SERIAL NO.:				
Information disclosure Statement				56822 (47126) 10/037,480				
				APPLICANT: G. CEVC et al.				
				FILING DATE: GROUP NO. January 4, 2002 1723				
			UNITE	STATES PATENT DOCU	MENTS			
EXAM.		DOCUMENT					FILING DATE	
INITIALS		NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIATE	
			FOR	REIGN PATENT DOCUME	NTS			
		DOCUMENT					TRANSLATION	
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES/NO	
•				OTHER DOCUMENTS				
•	CU	Lasch, J. et al., "Interactions of external lipids (lipids vesicles) with the skin" Journal of Liposome Research 5(3) pp. 543-569 (1995).						
	CV	Berger, M. "Oral Insulin 1922-1992: The History of Continuous Ambition and Failure" Heinrich- Heine-University, Dusseldorf, Germany						
	CW	Cevc. G. et al., "The skin: a pathway for systemic treatment with patches and lipid-based agent carriers" Advanced Drug Delivery Reviews 18 pp. 349-378 (1996).						
	СХ	M.L. Jacks on, et al. "SOLUBILIZATION OF PHOSPHATIDYLCHOLINE BILAYERS BY OCTYL GLUCOSIDE", biochemistry 1982, 21, 4576-4582.						
	CY	P. Vinson, et al. "VESICLE-MICELLE TRANSITION OF PHOSPHATIDYLCHOLINE AND OCTYL GLUCOSIDE ELUCIDATED BY CRYO-TRANSMISSION ELE TRON MICROSCOPY", Biophys. J., Biophysical Society Volume 56 October 1989 669-681.						
	CZ	K. Edwards, et al. "EFFECTS OF TRITON X-100 ON SONICATED LECITHIN VESICLES", Langmuir, Vol. 5, No. 2, 1989 pp. 473-478						
	EA	A. Brendzel, et al., "EFFECTS OF LIPID-SOLUBLE SUBSTANCES ON THE THERMOTROPIC PROPERTIES OF LIPOSOME FILTRATION", Biochimica et Biophysica Acta, 601 (1980) 260-270.						
	ЕВ			RIER AND STABILITY PRO IN VITRO AND IN VIVO", .				
EXAMINE	₹:				DATE:			
BOS2 31622					<u> </u>			